SynthesisScientific reports2015
Adjunctive Systemic Corticosteroids for Hospitalized Community-Acquired Pneumonia: Systematic Review and Meta-Analysis 2015 Update.
Synthesis in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.American journal of respiratory and critical care medicine · 2019Guideline
- Corticosteroids as adjunctive therapy in the treatment of influenza.The Cochrane database of systematic reviews · 2019Pooled it
- Corticosteroids for pneumonia.The Cochrane database of systematic reviews · 2017Pooled it
- Pooled it
- XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.Critical care medicine · 2019Trial
- Management of the Diagnosis and Treatment of Pneumonia in an Aging Society.Internal medicine (Tokyo, Japan) · 2025Review
- Advancements in the Management of Severe Community-Acquired Pneumonia: A Comprehensive Narrative Review.Cureus · 2023Review
- Host-Based Treatments for Severe COVID-19.Current issues in molecular biology · 2023Review
- Glucocorticoid therapy in respiratory illness: bench to bedside.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2022Review
- Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia.BMC pulmonary medicine · 2022Article
- Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study.Critical care (London, England) · 2021Observational
- Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia: A Review Article.Medical sciences (Basel, Switzerland) · 2021Review
- Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Mendelson's syndrome complicated by bacterial aspiration pneumonia triggered by right putamen bleeding: A case report.Respiratory medicine case reports · 2021Article
- Biomarker-Concordant Steroid Use in Critically Ill Patients with Pneumonia.Mayo Clinic proceedings. Innovations, quality & outcomes · 2020Article
- Article
- Genetic polymorphisms of rs9313422 G>C and rs41297579 G>A at the promoter of TIM-1 gene contribute to the risk of community-acquired pneumonia in children.Journal of clinical laboratory analysis · 2020Article
- Antimicrobial Therapy in the Context of the Damage-Response Framework: the Prospect of Optimizing Therapy by Reducing Host Damage.Antimicrobial agents and chemotherapy · 2020Review
- Corticosteroids for Community-Acquired Pneumonia: Overstated Benefits and Understated Risks.Chest · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous randomized controlled trials (RCTs) and meta-analyses evaluated the efficacy and safety of adjunctive corticosteroids for community-acquired pneumonia (CAP). However, the results from them had large discrepancies. The eligibility criteria for the current meta-analysis were original RCTs written in English as a full article that evaluated adjunctive systemic corticosteroids adding on antibiotic therapy targeting typical and/or atypical pathogen for treating hospitalized human CAP cases. Four investigators independently searched for eligible articles through PubMed, Embase, and Cochrane databases. Random model was used. The heterogeneity among original studies and subgroups was evaluated with the I(2) statistics. Of 54 articles that met the preliminary criteria, we found 10 eligible RCTs comprising 1780 cases. Our analyses revealed following pooled values by corticosteroids. OR for all-cause death: 0.80 (95% confidence interval (95% CI) 0.53-1.21) from all studies; 0.41 (95% CI 0.19-0.90) from severe-case subgroup; 0.21 (95% CI 0.0-0.74) from intensive care unit (ICU) subgroup. Length of ICU stay: -1.30 days (95% CI (-3.04)-0.44). Length of hospital stay: -0.98 days (95% CI (-1.26)-(-0.71)). Length to clinical stability: -1.16 days (95% CI (-1.73)-(-0.58)). Serious complications do not seem to largely increase by steroids. In conclusion, adjunctive systemic corticosteroids for hospitalized patients with CAP seems preferred strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.